Cargando…
Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil
A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy. Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation administration to patients with pulmonary arterial hyp...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682229/ https://www.ncbi.nlm.nih.gov/pubmed/33282202 http://dx.doi.org/10.1177/2045894020971509 |